Table of contents
June 2006 Vol 6 No 6
From the editors
p415 | doi:10.1038/nrc1925
Research Highlights
Metastasis: Stopping the spread
p417 | doi:10.1038/nrc1914
Tumour suppressors: Sssh, we are about to begin
p418 | doi:10.1038/nrc1909
Tumour suppressors: Form and function
p418 | doi:10.1038/nrc1919
In brief
Tumour Suppressors | MicroRNA | Oncogenes | Tumour Immunology
p419 | doi:10.1038/nrc1920
Trial Watch
Improving the tolerance of dose-dense chemotherapy | Testing for early breast cancer
p420 | doi:10.1038/nrc1915
Tumour suppressors: Less is more
p420 | doi:10.1038/nrc1916
In the news
The right choice?
p421 | doi:10.1038/nrc1917
Metastasis: New insights into tumour invasion
p421 | doi:10.1038/nrc1918
Circadian rhythms: Clocking on
p422 | doi:10.1038/nrc1921
Tumorigenesis: Nuclear bodies
p422 | doi:10.1038/nrc1922
Population genetics: Associated risk
p422 | doi:10.1038/nrc1923
Hepatocellular Carcinoma: Putting p53 in context
p423 | doi:10.1038/nrc1924
Reviews
Brain tumour stem cells
Angelo L. Vescovi, Rossella Galli & Brent A. Reynolds
p425 | doi:10.1038/nrc1889
Do alterations in the neural stem-cell population contribute to brain tumorigenesis? This review address how this knowledge might be used to identify new therapeutic strategies for the treatment of brain tumours, such as glioblastoma multiforme and medulloblastoma.
Evolving concepts in the pathogenesis of hairy-cell leukaemia
Enrico Tiacci, Arcangelo Liso, Miguel Piris & Brunangelo Falini
p437 | doi:10.1038/nrc1888
Gene-expression profiling and other studies have recently provided new insights into the biology of hairy-cell leukaemia (HCL). Such insights will facilitate differentiation of HCL from HCL-like disorders and lead to new targets for therapeutic intervention.
Metastasis: a question of life or death
Patrick Mehlen & Alain Puisieux
p449 | doi:10.1038/nrc1886
In this review the authors argue that the inhibition of cell death is an important characteristic of metastatic cancer cells. Will this view identify new treatments for metastatic disease?
p21-activated kinases in cancer
Rakesh Kumar, Anupama E. Gururaj & Christopher J. Barnes
p459 | doi:10.1038/nrc1892
p21-activated kinases (Paks) have recently been implicated in apoptosis and proliferation, as well as their established roles in cytoskeletal remodelling and motility. How do these roles contribute to tumorigenesis and are Paks a potential therapeutic target?
Perspectives
Innovation
The power and the promise of oncogene-induced senescence markers
Manuel Collado & Manuel Serrano
p472 | doi:10.1038/nrc1884
The recent finding that the induction of cellular senescence is associated with the premalignant stages of tumour progression indicates that markers of senescence might prove to be useful diagnostic and prognostic tools. This article presents some of the more promising candidates.
Science and society
Genetics as a tool to improve cancer outcomes: ethics and policy
Wylie Burke & Nancy Press
p476 | doi:10.1038/nrc1890
There are now many genetic tests that provide information about cancer risk. How should clinicians and policy makers ensure that the clinical uses of these tests maximize benefit and minimize harm?
